CTLA4 and neoplasm: We found that the use of a CTLA-4 blocker was found to be more likely to be beneficial for PC patients in Mcluster B. Therefore, the study of microbiome in the tumour microenvironment of PC can help provide new strategies for the selection of immunotherapy for patients with PC.